Alzheimer’s drugs lack benefit for mild cognitive impairment, researchers conclude

TORONTO – Researchers say drugs known as cognitive enhancers do not improve mental function in people with mild cognitive impairment.

Mild cognitive impairment, or MCI, is marked by memory lapses that may interfere with everyday tasks, but is not the same as normal aging.

However, up to 17 per cent of MCI patients go on to develop a dementia such as Alzheimer’s.

Cognitive enhancers are used in Alzheimer’s patients, but are sometimes given to people with MCI to enhance concentration, memory, alertness and mood. In Canada, doctors need special authorization to prescribe the drugs for MCI.

Researchers at St. Michael’s Hospital in Toronto reviewed eight randomized trials that compared four cognitive enhancers against placebo pills.

Their report in Monday’s Canadian Medical Association Journal says the drugs don’t benefit MCI patients in the long term and can cause nausea, diarrhea, vomiting and headaches.

“Our results do not support the use of cognitive enhancers for patients with mild cognitive impairment,” say theauthors, who looked at trials involving four cognitive enhancers — donepezil, rivastigmine, galantamine and memantine.

“Patients and their families should consider this information when requesting these medications. Similarly, health-care decision makers may not wish to approve the use of these medications for mild cognitive impairment, because these drugs might not be effective and are likely associated with harm.”

News from © The Canadian Press, . All rights reserved.
This material may not be published, broadcast, rewritten or redistributed.

Join the Conversation!

Want to share your thoughts, add context, or connect with others in your community? Create a free account to comment on stories, ask questions, and join meaningful discussions on our new site.

Leave a Reply

You must be logged in to post a comment.
The Canadian Press

The Canadian Press is Canada's trusted news source and leader in providing real-time, bilingual multimedia stories across print, broadcast and digital platforms.